<DOC>
	<DOC>NCT00172380</DOC>
	<brief_summary>To assess the overall response rate to docetaxel plus CDDP as neoadjuvant chemotherapy prior to surgery, followed by adjuvant docetaxel plus CDDP in chemonaive patients NSCLC Stage IIIa and IIIb.</brief_summary>
	<brief_title>Phase II Study of Docetaxel Plus CDDP for NSCLC Stage III</brief_title>
	<detailed_description />
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically or cytologically confirmed NSCLC, respectable NSCLC stage IIIa T12 N2 or or unresectable stage IIIb 2.KPS&gt;70% 3.Hb&gt;10g/dl,ANC&gt;2.0x109/L,Plt.&gt;100x109/L4.Tbil.&lt;1xULN,creatinine&lt;1xULN,creatinine clearance &gt;60 ml/min,GPT/GOT&lt;2.5xULN,ALP&lt;5xULN 1.Brain meta.2..Prior surgery,R/T, C/t or immunotherapy for NSCLC</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>